For the last 10 years we helped patients receive miltefosine also know as Impavido*  by licensing it from a company facing backlash for not launching as the market was too small and they couldn't find a partner willing to market the drug, so they asked up to help. Sales expectations at that time were less than $1M max per year.

Since then Orphan drug designations and patents have been filed to help over 2400 patients and generated over $100 M in Sales and $60+ Million USD dollars in profit for the licensor representing the majority of their positive cash flow while helping over 2300 patients with serious conditions such as:
- $5.3M PAM/Balamuthia (Brain Eating Amoeba)
- $21M Acanthamoeba (AK for the Eye)
- $0 Chemotherapy (donated)
- $7.2 M Other Donations
- $28M Leishmaniasis
- $.8M Fungal
- $.2 Vet